Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course

Multiple Sclerosis

Volumn 23, Issue 2, 2017, Pages 277-285

  Conway, Devon S ^a   Thompson, Nicolas R ^a   Cohen, Jeffrey A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

comorbidity; database; disease course; Multiple sclerosis; outcome measurement

Indexed keywords

ADULT; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OUTCOME; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEALTH IMPACT ASSESSMENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT HEALTH QUESTIONNAIRE 9; WALKING SPEED; COMPLICATION; MIDDLE AGED; PROCEDURES; QUALITY OF LIFE;

COMORBIDITY; DIABETES MELLITUS; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LONGITUDINAL STUDIES; LUNG DISEASES, OBSTRUCTIVE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; QUALITY OF LIFE;

EID: 85011824705     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458516650512     Document Type: Article

References (34)

1. Marrie RA, Horwitz RI,. Emerging effects of comorbidities on multiple sclerosis. Lancet Neurol 2010; 9 (8): 820-828.
2. Marrie RA, Horwitz R, Cutter G, et al. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology 2009; 72 (2): 117-124.
3. Marrie RA, Horwitz R, Cutter G, et al. Cumulative impact of comorbidity on quality of life in MS. Acta Neurol Scand 2012; 125 (3): 180-186.
4. Marrie RA, Cohen J, Stuve O, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. Mult Scler 2015; 21 (3): 263-281.
5. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010; 74 (13): 1041-1047.
6. Marrie RA, Miller AE, Sormani MP, et al. Recommendations for observational studies of comorbidity in multiple sclerosis. Neurology 2016; 86: 1446-1453.
7. Katzan I, Speck M, Dopler C, et al. The knowledge program: An innovative, comprehensive electronic data capture system and warehouse. AMIA Annu Symp Proc 2011; 2011: 683-692.
8. Schwartz CE, Vollmer T, Lee H,. Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Neurology 1999; 52 (1): 63-70.
9. Marrie RA, Goldman M,. Validity of performance scales for disability assessment in multiple sclerosis. Mult Scler 2007; 13 (9): 1176-1182.
10. Spitzer RL, Kroenke K, Williams JB,. Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999; 282 (18): 1737-1744.
11. Rudick RA, Cutter G, Reingold S,. The multiple sclerosis functional composite: A new clinical outcome measure for multiple sclerosis trials. Mult Scler 2002; 8 (5): 359-365.
12. Hojsgaard S, Halekoh U, Yan J,. The R package geepack for generalized estimating equations. J Stat Softw 2006; 15 (2): 1-11.
13. Yan J, Fine J,. Estimating equations for association structures. Stat Med 2004; 23 (6): 859-874; discussion 875-877, 879-880.
14. Yan J,. Geepack: Yet another package for generalized estimating equations. R-News 2002; 2-3: 12-14.
15. Rubin D,. Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons, 1987.
16. Van Buuren S, Brand JPL, Groothuis-Oudshoorn K, et al. Fully conditional specification in multivariate imputation. J Stat Comput Simul 2006; 76 (12): 1049-1064.
17. Van Buuren S, Groothuis-Oudshoorn CGM,. Mice: Multivariate imputation by chained equations in R. J Stat Softw 2011; 45 (3): 1-67.
18. Kang JH, Chen YH, Lin HC,. Comorbidities amongst patients with multiple sclerosis: A population-based controlled study. Eur J Neurol 2010; 17 (9): 1215-1219.
19. Marrie RA, Yu BN, Leung S, et al. Rising prevalence of vascular comorbidities in multiple sclerosis: Validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Mult Scler 2012; 18 (9): 1310-1319.
20. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple sclerosis severity score: Using disability and disease duration to rate disease severity. Neurology 2005; 64 (7): 1144-1151.
21. Moccia M, Lanzillo R, Palladino R, et al. The Framingham cardiovascular risk score in multiple sclerosis. Eur J Neurol 2015; 22 (8): 1176-1183.
22. Salerno JA, Murphy DG, Horwitz B, et al. Brain atrophy in hypertension. A volumetric magnetic resonance imaging study. Hypertension 1992; 20 (3): 340-348.
23. Nagai M, Hoshide S, Ishikawa J, et al. Ambulatory blood pressure as an independent determinant of brain atrophy and cognitive function in elderly hypertension. J Hypertens 2008; 26 (8): 1636-1641.
24. Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Mult Scler 2015; 21 (3): 318-331.
25. Weinstock-Guttman B, Zivadinov R, Horakova D, et al. Lipid profiles are associated with lesion formation over 24 months in interferon-beta treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry 2013; 84 (11): 1186-1191.
26. Weinstock-Guttman B, Zivadinov R, Mahfooz N, et al. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation 2011; 8: 127.
27. Tettey P, Simpson S Jr, Taylor B, et al. An adverse lipid profile is associated with disability and progression in disability, in people with MS. Mult Scler 2014; 20 (13): 1737-1744.
28. Tettey P, Simpson S Jr, Taylor B, et al. Adverse lipid profile is not associated with relapse risk in MS: Results from an observational cohort study. J Neurol Sci 2014; 340 (1-2): 230-232.
29. Weber MS, Youssef S, Dunn SE, et al. Statins in the treatment of central nervous system autoimmune disease. J Neuroimmunol 2006; 178 (1-2): 140-148.
30. Tremlett HL, Evans J, Wiles CM, et al. Asthma and multiple sclerosis: An inverse association in a case-control general practice population. QJM 2002; 95 (11): 753-756.
31. Kappus N, Weinstock-Guttman B, Hagemeier J, et al. Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016; 87: 181-187.
32. Martin DJ, Ul-Haq Z, Nicholl BI, et al. Cardiometabolic disease and features of depression and bipolar disorder: Population-based, cross-sectional study. Br J Psychiatry 2016; 208: 343-351.
33. Miller AE,. Teriflunomide: A once-daily oral medication for the treatment of relapsing forms of multiple sclerosis. Clin Ther 2015; 37 (10): 2366-2380.
34. Berkovich R,. Treatment of acute relapses in multiple sclerosis. Neurotherapeutics 2013; 10 (1): 97-105.